Crossject Société Anonyme (ALCJ.PA)
3.15 €
-0.13 (-3.82%)
Rating:
Recommendation:
-
| Symbol | ALCJ.PA |
|---|---|
| Price | 3.15 € |
| Beta | 1.733 |
| Volume Avg. | 0.09M |
| Market Cap | 81.923M |
| Shares () | - |
| 52 Week Range | 1.408-3.94 |
| 1y Target Est | - |
| DCF Unlevered | ALCJ.PA DCF -> | |
|---|---|---|
| DCF Levered | ALCJ.PA LDCF -> | |
| ROE | 883.35% | Strong Buy |
| ROA | -25.13% | Sell |
| Operating Margin | - | |
| Debt / Equity | -675.17% | Strong Sell |
| P/E | - | |
| P/B | -11.61 | Strong Sell |
About
Download (Excel)Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.